-
Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. 2025 Jan 01; 131(1):e35587. Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas A. PMID: 39342463; PMCID: PMC11694162.
-
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226. Zhuang E, Uchio E, Lilly M, Zi X, Fruehauf JP. PMID: 34649352; PMCID: PMC9886492.
-
HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Mol Cancer Res. 2019 08; 17(8):1675-1686. Parmakhtiar B, Burger RA, Kim JH, Fruehauf JP. PMID: 31088908.
-
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2018 08; 82(2):353-360. Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG. PMID: 29943192; PMCID: PMC6060847.
-
Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89. Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP. PMID: 25336084.
-
A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. Cancer Chemother Pharmacol. 2013 Jul; 72(1):263-7. Eroglu Z, Fruehauf JP. PMID: 23636451.
-
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol. 2013 Mar 11; 32(2):123-32. Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R, Borden EC. PMID: 23202046; PMCID: PMC3615071.
-
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecol Oncol. 2012 Sep; 126(3):375-80. Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. PMID: 22683587.
-
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012 Jan 01; 30(1):34-41. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ. PMID: 22124101; PMCID: PMC4669379.
-
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011 Dec 01; 17(23):7462-9. Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O. PMID: 21976544.
-
Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1081-7. Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP. PMID: 21769667; PMCID: PMC3180631.
-
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011 Jun 01; 17(11):3841-9. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. PMID: 21531811.
-
Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia. 2011 Feb; 13(2):108-19. Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X. PMID: 21403837; PMCID: PMC3033590.
-
Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis. 2010 Dec; 13(4):305-15. Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP. PMID: 20927579; PMCID: PMC2980626.
-
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol. 2010 Dec; 119(3):484-90. Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. PMID: 20870280; PMCID: PMC2975758.
-
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):417-21. Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA. PMID: 20846714; PMCID: PMC2978536.
-
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther. 2010 Jul; 9(7):2068-78. Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH. PMID: 20606044; PMCID: PMC4383085.
-
Targeted therapy in ovarian cancer. J Oncol. 2010; 2010:740472. Willmott LJ, Fruehauf JP. PMID: 20130818; PMCID: PMC2814233.
-
Redox-related antimelanoma activity of ATN-224. Melanoma Res. 2009 Dec; 19(6):350-60. Trapp V, Lee K, Doñate F, Mazar AP, Fruehauf JP. PMID: 22760066.
-
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Mar; 116(3):452-8. Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbridge EJ. PMID: 19913895; PMCID: PMC2822024.
-
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res. 2009 May 15; 69(10):4484-92. Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, Ferrari M, Cristini V. PMID: 19366802; PMCID: PMC2720602.
-
Immunohistochemical basis for adjuvant anti-angiogenic targeted therapy for renal carcinoid: initial case report. Urol Oncol. 2011 Jan-Feb; 29(1):85-9. Finley DS, Narula N, Valera VA, Merino MJ, Fruehauf J, Wu ML, Linehan WM, Clayman RV. PMID: 19110452; PMCID: PMC4519232.
-
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar; 112(3):583-9. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP. PMID: 19110305; PMCID: PMC2858218.
-
Reactive oxygen species: an Achilles' heel of melanoma? Expert Rev Anticancer Ther. 2008 Nov; 8(11):1751-7. Fruehauf JP, Trapp V. PMID: 18983235.
-
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol. 2008 Oct; 28(20):6496-509. Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST. PMID: 18694961; PMCID: PMC2577410.
-
The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol. 2008 Dec; 70(6):649-52; discussion 653. Mathews MS, Linskey ME, Hasso AN, Fruehauf JP. PMID: 18261776.
-
Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer. 2007 Dec 01; 110(11):2519-27. Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, Ranger-Moore J, Duckett L, Bangert J, Fruehauf JP, Alberts DS. PMID: 17932890.
-
Fluorescence activated cell sorting (FACS) using RNAlater to minimize RNA degradation and perturbation of mRNA expression from cells involved in initial host microbe interactions. J Microbiol Methods. 2007 Jul; 70(1):205-8. Nishimoto KP, Newkirk D, Hou S, Fruehauf J, Nelson EL. PMID: 17512621.
-
Reactive oxygen species: a breath of life or death? Clin Cancer Res. 2007 Feb 01; 13(3):789-94. Fruehauf JP, Meyskens FL. PMID: 17289868.
-
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther. 2006 Oct; 6(10):1361-76. Sanga S, Sinek JP, Frieboes HB, Ferrari M, Fruehauf JP, Cristini V. PMID: 17069522.
-
Pharmacogenomics of colorectal cancer prevention and treatment. Cancer Invest. 2006 Oct; 24(6):630-9. Nguyen H, Tran A, Lipkin S, Fruehauf JP. PMID: 16982469.
-
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res. 2006 Aug 01; 12(15):4523-32. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R. PMID: 16899598.
-
A tale of two growth factors. Pharmacotherapy. 2006 Mar; 26(3):443-4; discussion 444. Fruehauf JP, Kong KM, Wong SF, Chan HO. PMID: 16503728.
-
EGFR function and detection in cancer therapy. J Exp Ther Oncol. 2006; 5(3):231-46. Fruehauf J. PMID: 16528973.
-
Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study. Gynecol Oncol. 2005 Oct; 99(1):84-91. Tewari D, Monk BJ, Al-Ghazi MS, Parker R, Heck JD, Burger RA, Fruehauf JP. PMID: 16109440.
-
In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol. 2005 May 20; 23(15):3641-3; author reply 3646-8. Fruehauf JP, Alberts DS. PMID: 15908686.
-
The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res. 2005 May 15; 11(10):3733-42. Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE. PMID: 15897570.
-
Docetaxel and vinorelbine plus GM-CSF in malignant melanoma. Oncology (Williston Park). 2005 Apr; 19(4 Suppl 2):19-22. Fruehauf JP, Kong KM, Jakowatz JG. PMID: 15934496.
-
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res. 2004 Aug 15; 10(16):5403-17. Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D. PMID: 15328178.
-
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol. 2004 Feb; 66(3):365-75. Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. PMID: 15015670.
-
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol. 2004 Jan; 92(1):160-6. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP. PMID: 14751152.
-
Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer. 2003 Oct 15; 98(8):1658-63. Del Carmen MG, Smith Sehdev AE, Fader AN, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow RE. PMID: 14534882.
-
Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging. 2003 Oct; 18(4):467-77. Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, Kyshtoobayeva A, Chen SC, Hsueh S, McLaren CE, Wan YL. PMID: 14508784.
-
Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs. 2003 Sep; 14(8):659-62. Sommers KR, Kong KM, Bui DT, Fruehauf JP, Holcombe RF. PMID: 14501389.
-
Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry A. 2003 Jun; 53(2):67-78. Park SW, Lomri N, Simeoni LA, Fruehauf JP, Mechetner E. PMID: 12766968.
-
Assay-assisted treatment selection for women with breast or ovarian cancer. Recent Results Cancer Res. 2003; 161:126-45. Fruehauf JP, Alberts DS. PMID: 12528805.
-
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring. Technol Cancer Res Treat. 2002 Dec; 1(6):479-88. Su MY, Yu H, Chiou JY, Wang J, Nalcioglu O, Fruehauf JP, Mehta RS, Baick CH. PMID: 12625775.
-
Development of an in vitro chemo-radiation response assay for cervical carcinoma. Gynecol Oncol. 2002 Nov; 87(2):193-9. Monk BJ, Burger RA, Parker R, Radany EH, Redpath L, Fruehauf JP. PMID: 12477451.
-
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 2002 Oct; 87(1):8-16. Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP. PMID: 12468336.
-
Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J Neurooncol. 2002 Jun; 58(2):115-23. Haroun RI, Clatterbuck RE, Gibbons MC, Burger PC, Parker R, Fruehauf JP, Brem H. PMID: 12164682.
-
Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. Breast Cancer Res Treat. 2002 Jan; 71(2):95-102. Ellis RJ, Fabian CJ, Kimler BF, Tawfik O, Mayo MS, Decelis CR, Jewell WR, Connor C, Modrell C, Praeger M, McGinness M, Mehta R, Fruehauf JP. PMID: 11881914.
US